One of the major puzzles in medical research and public health systems worldwide is
Alzheimer's disease (AD), reaching nowadays a prevalence near 50 million people. This is a …

The number of elderly people nowadays is rapidly increasing, especially in the developed
countries. This brings about serious problems such as occurrence of diseases connected …

Alzheimer's disease (AD) represents an increasing worldwide healthcare epidemic.
Secondary preventive disease-modifying treatments under clinical development are …

Alzheimer's disease (AD) is the most common cause of dementia associated with a
progressive neurodegenerative disorder, with a prevalence of 44 million people throughout …

The foundation of current Alzheimer's disease (AD) treatment involves pharmacological and
nonpharmacological management and care planning predicated on patient-centered …

During this decade, breakthrough conceptual shifts have commenced to emerge in the field
of Alzheimer's disease (AD) recognizing risk factors and the non-linear dynamic continuum …

Alzheimer's disease (AD) is a neurodegenerative dementia that affects nearly 50 million
people worldwide and is a major source of morbidity, mortality, and healthcare expenditure …

Neurodegeneration is a feature of many debilitating, incurable age-dependent diseases that
affect the nervous system and represent a major threat to the health of elderly persons …

Article purpose The clinical approach to Alzheimer's disease (AD) is challenging, particularly
in high-functioning individuals. Accurate diagnosis is crucial, especially given the significant …

Novel agents addressing non-amyloid, non-tau targets in Alzheimer's Disease (AD)
comprise 70% of the AD drug development pipeline of agents currently in clinical trials. Most …